Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | THPO | P40225 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zelandopam SCHEMBL18311503 | 1.00 | PARP1 (0.76) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL9667773 | 1.00 | PARP1 (0.76) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL8904601 | 0.98 | PARP1 (0.74) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL29424271 | 0.98 | PARP1 (0.74) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL8904866 | 0.97 | PARP1 (0.72) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL8904230 | 0.97 | PARP1 (0.72) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL8904713 | 0.97 | PARP1 (0.72) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL8904241 | 0.97 | PARP1 (0.72) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL8904707 | 0.97 | PARP1 (0.72) | PARP1MAPK1CYP3A4TSHRNFKB1 | |
| Zelandopam SCHEMBL9453174 | 0.97 | PARP1 (0.72) | PARP1MAPK1CYP3A4TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PARP1 4561/4885MAPK1 2443/4885CYP3A4 1499/4885 |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | HMGB1, PAICS, CCL2 | PARP1 933/4885MAPK1 3293/4885CYP3A4 729/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | PARP1 3687/4885MAPK1 4467/4885CYP3A4 212/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | PARP1 3687/4885MAPK1 4467/4885CYP3A4 212/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | PARP1 3711/4885MAPK1 4494/4885CYP3A4 209/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | PARP1 3711/4885MAPK1 4494/4885CYP3A4 209/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | PARP1 3711/4885MAPK1 4494/4885CYP3A4 209/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | PARP1 4387/4885MAPK1 2752/4885CYP3A4 1035/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | PARP1 4595/4885MAPK1 2393/4885CYP3A4 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.